Aster DM Healthcare FY26: Consolidated Growth Shines Amidst Standalone One-Offs

Aster DM Healthcare announced its audited financial results for the fiscal year ended March 31, 2026. The company's statutory auditors, Deloitte Haskins & Sells, issued an unmodified opinion on the financial statements. In a move signaling management confidence, the Board of Directors also approved an interim dividend of ₹3 per equity share.

While consolidated revenue climbed 12% to ₹4,643.22 crore and consolidated Profit Before Tax (PBT) increased to ₹569.69 crore from ₹471.06 crore in the prior year, the standalone PBT showed a significant drop. Standalone revenue grew to ₹2,615.70 crore from ₹2,320.48 crore. However, standalone PBT fell to ₹374.20 crore, a sharp contrast to ₹6,288.25 crore in FY25. This decline was attributed to an investment write-down of ₹57.24 crore impacting FY26 results and a high base in FY25 due to a substantial dividend received from the sale of its GCC business.

Why This Matters

The financial results reveal a clear divergence between Aster DM Healthcare's consolidated and standalone performance. Strong operational growth across the entire network is reflected in the consolidated figures. Conversely, the standalone numbers are being influenced by significant one-time events. Investors should focus beyond the standalone PBT drop to assess the underlying health and growth trajectory of the company's Indian operations. The approved interim dividend underscores the management's confidence in the company's ongoing cash generation capabilities, even with these accounting adjustments.

The Backstory

Aster DM Healthcare completed the strategic separation of its India and GCC businesses in April 2024. This involved selling a stake in its GCC operations to a consortium led by Fajr Capital, with the Moopen family retaining a significant stake in the Indian entity. The high standalone PBT in FY25 was a direct consequence of a substantial dividend received from this GCC business sale. The current FY26 standalone results were further affected by an investment write-down.

The company has ambitious growth plans for India, aiming to add 1,500-2,000 incremental beds over the next 3-4 years through brownfield and greenfield expansions.

What's Next

With the business segregation complete, attention now turns to Aster DM Healthcare's strategic expansion plans in India. The company also confirmed it does not meet the criteria for SEBI's 'Large Corporate' classification, based on its current borrowing levels.

Risks to Watch

A GST order from the Kochi Commissionerate has demanded ₹72.91 lakh (tax and penalty) for alleged non-payment of GST on insurance processing fees for FY19-24. The company stated this will have no material financial impact and plans to pursue legal remedies.

A minor violation of the Insider Trading Code was reported in March 2025 involving a small trade, with the company taking corrective actions.

Peer Comparison

Aster DM Healthcare's consolidated revenue of ₹4,643 crore for FY26 is in line with the growth seen across major Indian hospital chains. In FY24, peers like Apollo Hospitals Enterprise saw an 11.3% rise in ARPOB, while Max Healthcare reported a 12% increase. Fortis Healthcare and Narayana Hrudayalaya also posted revenue growth, with Narayana Health's revenue reaching ₹5,000 crore in FY24.

Industry Trends

The hospital industry is seeing increasing Average Revenue Per Occupied Bed (ARPOB). For major Indian private hospital chains, ARPOB per day reached an estimated ₹49,800 in FY24, reflecting rising operational metrics across the sector. This trend supports the observed consolidated growth at Aster DM Healthcare.

What to Track

Progress on India's expansion plans, including new bed additions and geographical reach.

Management commentary on the drivers behind the consolidated growth and the specific reasons for the standalone investment write-down.

Performance of the separated GCC business and its strategic direction.

Any further developments on the GST order and the company's legal recourse.